title: [A CHOP-21 course efficacy in therapy of diffuse large B-cell lymphosarcoma].
abstract: OBJECTIVE
  To examine efficacy of polychemotherapy (PCT) CHOP-21 in patients with diffuse large B-cell lymphosarcoma (DLBCL).
  
  
  METHODS
  Fifty-five DLBCL patients received first-line therapy according to CHOP-21 program in 1996-2004. The diagnosis was made by WHO criteria.
  
  
  RESULTS
  Initially, 37 patients had lymph node lesions, 18--nonlymphatic lesions. Complete remissions were achieved in 49% (56.7% in nodal lesions, 33.3% in extranodal ones). Overall 5-year survival was 35%, event-free--25%, for patients with nodal lesions--36 and 32%, respectively, extranodal lesions--35 and 22%, respectively. Overall 5-year and event-free survival in patients with local lesions was 85 and 75%, generalized--25 and 20%, respectively. In patients with involvement of the gastrointestinal tract 3-year overall and event-free survival reached 50 and 45%. Event-free survival was not seen in patients with extranodal lesions of other locations in overall 3-year survival 45%.
  
  
  CONCLUSIONS
  PCT program CHOP-21 was effective in DLBCL patients with local nodular lesions except cases with large-size tumors, invasion in the adjacent organs and tissues and isolated gastric lesion.
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: T N
authors.initials: TN
authors.lastname: Moiseeva
authors.forename: E E
authors.initials: EE
authors.lastname: Zybunova
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: R S
authors.initials: RS
authors.lastname: Samoĭlova
authors.forename: I A
authors.initials: IA
authors.lastname: Vorob'ev
authors.forename: Iu Iu
authors.initials: IuIu
authors.lastname: Lorie
authors.forename: O V
authors.initials: OV
authors.lastname: Margolin
authors.forename: E A
authors.initials: EA
authors.lastname: Giliazitdinova
authors.forename: A V
authors.initials: AV
authors.lastname: Gubkin
authors.forename: N G
authors.initials: NG
authors.lastname: Chernova
authors.forename: V V
authors.initials: VV
authors.lastname: Ryzhko
authors.forename: E G
authors.initials: EG
authors.lastname: Gemdzhian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone